Overview

Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma

Status:
Unknown status

Trial end date:
2020-01-01

Target enrollment:

Participant gender:

Summary

This randomized phase III trial is studying gefitinib and synchronous pemetrexed/cisplatin chenmotherapy to see how well it works compared to pemetrexed/cisplatin chenmotherapy alone in treating patients who have undergone surgery for stage II-IIIA(N1-N2) lung adenocarcinoma with EGFR activating mutation in Asian population.

Phase:

Phase 3

Details

Lead Sponsor:

Tang-Du Hospital

Treatments:

Cisplatin
Gefitinib
Pemetrexed